| Prev Close | 1.84 |
| Open | 1.82 |
| Day Low/High | 1.81 / 1.87 |
| 52 Wk Low/High | 1.46 / 7.85 |
| Volume | 28.92K |
| Avg Volume | 64.70K |
| Exchange | AMEX |
| Shares Outstanding | 16.35M |
| Market Cap | 30.09M |
| EPS | -0.50 |
| P/E Ratio | 7.36 |
| Div & Yield | N.A. (N.A) |
Latest News
Can-Fite Establishes Clinical Advisory Board For NAFLD/NASH
- Board members are Key Opinion Leaders in the field of liver diseases
New Preclinical Data On Can-Fite's Namodenoson To Be Presented At 1st International Conference On Fatty Liver In Seville, Spain On June 2, 2017
- Data show Namodenoson both prevents and inhibits liver fibrosis
Can-Fite's Liver Protective Drug Namodenoson Enters Phase II Trial For Treatment Of NAFLD/NASH
- $35 Billion treatment market by 2025 with need for an FDA approved drug
New Preclinical Data Show Can-Fite's Namodenoson (CF102) Prevents Progression Of Liver Fibrosis
- Phase II trial to treat NAFLD/NASH expected to commence in 2017
Can-Fite Gears Up For ACRobat, Its Phase III Trial Of Piclidenoson In Rheumatoid Arthritis
-- Patient enrollment to commence Q2 2017
Can-Fite Receives IRB Approval To Commence Patient Enrollment In Phase II NAFLD/NASH Trial In Q1 2017
Compelling unmet need for NAFLD/NASH drug due to lack of FDA approved drug for the indication and an estimated $35 billion treatment market by 2025
Can-Fite Receives $500,000 Payment As Part Of $3 Million Distribution Deal For Liver Cancer Drug Namodenoson (CF102) In South Korea
Additional $2.5 million in milestone payments plus 23% royalties upon commercialization in South Korea
New Preclinical Data Show Can-Fite's Namodenoson (CF102) Inhibits Liver Fibrosis -- Supports Potential Efficacy In Treatment Of NASH
Phase II trial to treat NAFLD/NASH expected to commence in 2017
Can-Fite Receives Notice Of Allowance From U.S. Patent And Trademark Office For Erectile Dysfunction Drug
Broad patent coverage for both composition of matter & specific receptor ligands for the treatment of erectile dysfunction
Can-Fite Advances Towards A Pivotal Phase III Clinical Trial In Psoriasis With Piclidenoson (CF101) Following Reaching Agreement With EMA
- Phase III clinical study designed to establish Piclidenoson is superior to placebo as primary endpoint and non-inferior to Otezla® at week 32 as secondary endpoint
Can-Fite Signs Distribution Deal For Liver Cancer Drug CF102 In South Korea
- Deal provides for up to $3,000,000 in upfront and milestone payments & a percentage rate of royalty payments in the low twenties
Can-Fite Submits Protocol For Phase II Trial Of CF102 In The Treatment Of NAFLD/NASH
- Leading Israeli medical institutions Hadassah and Rabin Medical Centers to be included in the trial
Ratings Changes Today
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BKD, CCE, CFBK, FIT Downgrades: FWRD, SIG, VIA Initiations: CANF Read on to get TheStreet Quant Ratings' detailed report:
Can-Fite Reports New Data On CF102's Liver Protective & Regenerative Properties Published In Scientific Journal
- Article published in Molecular Medicine Reports
Can-Fite Receives Notice Of Allowance For Psoriasis Patent In Europe Ahead Of Phase III Trial
- 2.4 million Europeans living with moderate-to-severe psoriasis
Can-Fite Completes Phase II Study Design For CF102 In The Treatment Of NASH/NAFLD
- NASH/NAFLD are the leading cause of liver disease in Western countries
Can-Fite Reports New Data Showing Its Psoriasis Drug May Offer Efficacy Similar To Industry Leading Biologics Without Harmful Side Effects
- Similar to biologics, Piclidenoson (CF101) inhibits inflammatory proteins IL-17 and IL-23
Can-Fite Submits Psoriasis Phase III Protocol And Registration Plan To EMA For Piclidenoson (CF101)
- Phase III protocol is a head-to-head trial comparing Piclidenoson to Otezla®
Can-Fite To Exhibit At Bio International Convention In San Francisco On June 6-9, 2016
Company also to participate as a member of the Israeli Biotech Delegation at Perspectives on Biotech Investing on June 6
Can-Fite Reaches Agreement With EMA On Pivotal Phase III Clinical Trial With Piclidenoson (CF101) In Rheumatoid Arthritis
- EMA suggests development of Piclidenoson as a first line therapy and alternative for methotrexate, the standard of care for rheumatoid arthritis
